The 5 most recent market catalysts affecting $HELP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 55
Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026
Cybin Inc. (soon to be Helus Pharma Inc.) held its annual and special shareholder meeting, where key corporate governance matters were approved. The most significant item was the f…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 65
TD Cowen Maintains Buy on Helus Pharma, Raises Price Target to $62
TD Cowen analyst Ritu Baral maintained a 'Buy' rating on Helus Pharma and dramatically raised the price target from $8 to $62. This significant increase in the price target, repres…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 92
Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate
Helus Pharma (HELP) announced Q1 earnings per share of $(0.91), which was a substantial beat against the consensus analyst estimate of $(1.07). This 14.95% beat, coupled with a 17.…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 75
Helus Pharma Appoints Michael Halstead CEO, Effective Immediately
Helus Pharma, a clinical-stage pharmaceutical company, has appointed Michael Halstead as its new CEO, effective immediately. This is a significant leadership change for any company…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 65
Wells Fargo Initiates Coverage On Helus Pharma with Overweight Rating, Announces Price Target of $16
Wells Fargo analyst Benjamin Burnett initiated coverage on Helus Pharma (HELP) with an 'Overweight' rating and a $16 price target. This is a significant event for a smaller company…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.